NCT03958123 - Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects | Biotech Hunter

Enrollment

171

Participants

Timeline

Start Date

July 10, 2013

Primary Completion Date

November 27, 2013

Study Completion Date

November 27, 2013

Conditions

Prolonged QTc IntervalPharmacokinetic

Interventions

DRUG

100 μg cebranopadol

Encapsulated 100 μg cebranopadol tablet.

DRUG

200 μg cebranopadol

Encapsulated 200 μg cebranopadol tablet.

DRUG

400 μg cebranopadol

Encapsulated 400 μg cebranopadol tablet.

DRUG

Placebo to cebranopadol encapsulated tablets

Matching placebo to cebranopadol encapsulated tablet.

DRUG

400 mg Moxifloxacin

Encapsulated 400 mg moxifloxacin tablet.

DRUG

Placebo to moxifloxacin encapsulated tablets

Matching placebo to moxifloxacin (400 mg) encapsulated tablet.

Trial Locations (1)

US001 Contract research organization, West Bend